U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07561190) titled 'Multidimensional Omics Analysis in Malignant Pleural Mesothelioma' on April 16.
Brief Summary: Malignant pleural mesothelioma (MPM) is a rare and incurable cancer. Most patients are diagnosed with unresectable disease for which treatment options are limited. The lack of prognostic biomarkers further complicates the decision-making. Recently, the introduction of immune checkpoint inhibitors (ICIs) has marked a shift but has failed to produce significant benefits for a large proportion of patients. Maximizing the efficiency of ICIs and developing new protocols to improve drug efficacy is the best possible strategy for improving the life...